AI Insight
A minimally invasive procedure called duodenal mucosal resurfacing (DMR) may help patients maintain weight loss after discontinuing GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy). In a clinical trial, participants who underwent DMR regained significantly less weight following medication cessation compared to those who did not receive the procedure. The technique involves ablating and renewing the mucosal lining of the duodenum, which is hypothesized to reset metabolic signaling pathways involved in glucose regulation and energy balance.
Why it matters
Weight regain after stopping GLP-1 medications is a well-documented clinical challenge, and a durable, non-surgical intervention to preserve metabolic benefits could reduce long-term dependence on expensive drugs. If validated in larger trials, DMR could represent an important complementary strategy in obesity management.
A new minimally invasive procedure may help people keep weight off after stopping popular drugs like Ozempic and semaglutide—something most patients struggle with. In a clinical trial, those who underwent a technique called duodenal mucosal resurfacing regained far less weight compared to others after discontinuing the medication. The procedure works by renewing the lining of the upper small intestine, potentially “resetting” metabolism and preserving the benefits of weight loss.